Open-label Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Auriхim

PHASE1CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions
Lymphoma, Non-HodgkinLymphoma, Follicular
Interventions
DRUG

Aurixim

Administration will be performed once a week during 4-week induction period, and then once per 12 weeks during supporting period, if necessary. Total maximum duration of the investigational therapy - 1 year, during which patients will receive up to 8 infusions of Aurixim.

Trial Locations (3)

105203

"Federal State Budgetary Institution National Medical-Surgical Center n.a. N.I.Pirogov of the Ministry of Health of the Russian Federation", Moscow

115478

"Federal State Budgetary Institution Russian Oncological Scientific Center n.a. N.N.Blokhin of the Russian Academy of Medical Sciences", Moscow

606019

"State Budgetary Public Healthcare Institution of the Nizhni Novgorod Region Hospital of Ambulance of Dzerzhinsk city", Dzerzhinsk

All Listed Sponsors
lead

Biointegrator LLC

INDUSTRY

NCT03057418 - Open-label Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Auriхim | Biotech Hunter | Biotech Hunter